ASX:AN1

Anagenics (AN1) Stock Price, News & Analysis

Today's Range
N/A
50-Day Range
N/A
52-Week Range
N/A
Volume
N/A
Average Volume
N/A
Market Capitalization
N/A
P/E Ratio
N/A
Dividend Yield
0.88%
Price Target
N/A

About Anagenics

Anagenics Limited operates as a health and beauty tech company in Australia, New Zealand, and internationally. It develops and sells FGF5 inhibitor formulations; over-the-counter (OTC), cosmetic antiaging, and longevity targeting products; and imports and distributes international and local skin care and wellbeing products under the Thalgo, Hydro Peptide, Comfort Zone, Priori, and Inika Organic brand names. The company also develops, manufactures, and markets beauty and wellness brands comprising Uspa and evolis. It offers its products through various channels, including clinics, retail stores, wholesale pharmacy and spa/salons, online ecommerce, and cross border export markets. The company was formerly known as Cellmid Limited and changed its name to Anagenics Limited in December 2021. Anagenics Limited was incorporated in 2004 and is based in Sydney, Australia.

AN1 Stock News Headlines

See More Headlines
Receive AN1 Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Anagenics and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry
Household & Personal Products
Sub-Industry
N/A
CIK
N/A
Fax
N/A
Employees
N/A
Year Founded
N/A

Profitability

Net Income
$-2,580,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$10.20 million
Book Value
A$0.02 per share

Miscellaneous

Free Float
N/A
Optionable
Not Optionable
Beta
-1.01
7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google Cover

Growth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.

Get This Free Report

This page (ASX:AN1) was last updated on 4/23/2024 by MarketBeat.com Staff

From Our Partners